<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031572</url>
  </required_header>
  <id_info>
    <org_study_id>PI20/00338</org_study_id>
    <nct_id>NCT05031572</nct_id>
  </id_info>
  <brief_title>Energy -Sensing Metabolites in Caloric Restriction</brief_title>
  <official_title>New Energy-sensing Metabolites: Beneficial Effects on Metabolic Health in Obesity Comparing Diary Caloric Restriction vs Intermittent Fasting. A Randomized Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Investigacio Sanitaria Pere Virgili</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Investigacio Sanitaria Pere Virgili</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      General integrated goal of the coordinated project:&#xD;
&#xD;
      To elucidate the role of succinate and other metabolites derived from the intestinal&#xD;
      microbiota such as Short Chain Fatty Acids (SCFAs), as energy sensing metabolites in the&#xD;
      context of obesity and type 2 diabetes (T2D).&#xD;
&#xD;
      Specific objectives of Subproject 1 (SP1): 1a. - To investigate whether intermittent fasting&#xD;
      (IF) is better than Continued Daily Caloric Restriction (DCR) in terms of metabolic&#xD;
      improvement through the study of: 1) the dynamics of gastrointestinal hormones and energy&#xD;
      sensing metabolites, 2) the intestinal microbiome, 3) variability on succinate and SCFAs,&#xD;
      MCFAs and Biliary Acid after weight loss; Methodology: clinical study: randomized, cross-over&#xD;
      design, study participants (n=15) will consume either lifestyle recommendations for a healthy&#xD;
      Mediterranean diet under a continued caloric restriction diet (DCR) or will undertake an&#xD;
      intermittent (IF) protocol. Clinical, anthropometrical and functional studies. Metabolomics&#xD;
      for gut derived metabolites in plasma. Enteroendocrine gastrointestinal dynamics. Metagenomic&#xD;
      analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate whether IF is better than DCR in terms of metabolic improvement through the&#xD;
      study of:&#xD;
&#xD;
        1. the dynamics of gastrointestinal hormones and energy sensing metabolites&#xD;
&#xD;
        2. the intestinal microbiome&#xD;
&#xD;
        3. variability on succinate and SCFAs MCFAs and BA after weight loss&#xD;
&#xD;
      Human study protocol:&#xD;
&#xD;
      A pilot clinical trial in human study participants will be assayed. Participants for&#xD;
      intermittent fasting (IF) will be asked to fast for 24 hours on two days of the week (2/5&#xD;
      protocol).&#xD;
&#xD;
      1A.-Design: Utilizing a randomized, cross-over design, study participants (n=15) will consume&#xD;
      either lifestyle recommendations for a healthy Mediterranean diet under a continued daily&#xD;
      caloric restriction diet (DCR) or will undertake an intermittent (IF) protocol. Each study&#xD;
      period will be 8 weeks - total study period will be 16 weeks + a 4-week washout period&#xD;
      between dietary exposures. The study participants will be adults who have obesity with a Body&#xD;
      Mass Index (BMI)25 kg/m2 and 40 kg/m2 and have no contraindications for intermittent fasting&#xD;
      (see inclusion and exclusion criteria below).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>clinical study: randomized, cross-over design, study participants will consume either lifestyle recommendations for a healthy Mediterranean diet under a continued caloric restriction diet (DCR) or will undertake an intermittent (IF) protocol</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of glucose)</measure>
    <time_frame>basal and after 8 weeks</time_frame>
    <description>Plasma concentrations of glucose during a meal test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of insulin)</measure>
    <time_frame>basal and after 8 weeks</time_frame>
    <description>Plasma concentrations of insulin during a meal test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of glucose after crossing arm)</measure>
    <time_frame>at beginning of week 12 vs week 20</time_frame>
    <description>Plasma concentrations of glucose during a meal test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate whether IF is better than DCR in terms of metabolic improvement through the study (change in the secretory pattern of insulin after crossing arm)</measure>
    <time_frame>at beginning of week 12 vs week 20</time_frame>
    <description>Plasma concentrations of insulin during a meal test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) the dynamics of gastrointestinal hormones and energy sensing metabolites</measure>
    <time_frame>8 weeks - 20 weeks</time_frame>
    <description>GLP-1; GLP-2 during a meal test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2) Analysis of microbial species in fecal samples (gut flora)</measure>
    <time_frame>8 weeks - 20 weeks</time_frame>
    <description>intestinal microbiome after each interventional period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variability on succinate after weight loss</measure>
    <time_frame>8 weeks - 20 weeks</time_frame>
    <description>quantification of succinate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variability on Short-chain fatty acids (SCFAs) after weight loss</measure>
    <time_frame>8 weeks - 20 weeks</time_frame>
    <description>quantification of SCFAs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variability on Medium-chain fatty acids (MCFAs) after weight loss</measure>
    <time_frame>8 weeks - 20 weeks</time_frame>
    <description>quantification of MACFAs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variability on biliary acids (BA) after weight loss</measure>
    <time_frame>8 weeks - 20 weeks</time_frame>
    <description>quantification of BA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Sensitivity/Resistance</condition>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>conventional caloric restriction diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>(DCR protocol): lifestyle recommendations for a healthy Mediterranean diet under a continued daily caloric restriction diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermitent fasting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fasting for two days (non-consecutive) out of seven, with the fasting days separated by at least one day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dietary intervention</intervention_name>
    <description>Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis</description>
    <arm_group_label>Intermitent fasting</arm_group_label>
    <arm_group_label>conventional caloric restriction diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  White men and women between 18 and 65 years of age.&#xD;
&#xD;
          -  BMI range between 25 and 40 kg/m2&#xD;
&#xD;
          -  Absence of underlying pathology in medical and physical examination, except for those&#xD;
             related to excess weight.&#xD;
&#xD;
          -  Signature of the informed consent for participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious systemic disease not related to obesity, such as cancer, kidney or severe&#xD;
             liver disease.&#xD;
&#xD;
          -  Systemic diseases with intrinsic inflammatory activity (autoimmune diseases such as&#xD;
             rheumatoid arthritis and asthma)&#xD;
&#xD;
          -  Pregnancy and lactation.&#xD;
&#xD;
          -  Vegetarians or subjects subjected to an irregular diet.&#xD;
&#xD;
          -  Patients with severe eating disorders.&#xD;
&#xD;
          -  Patients with clinical symptoms and signs of infection in the previous month.&#xD;
&#xD;
          -  Patients with chronic anti-inflammatory steroid treatments and/or nonsteroidal&#xD;
             anti-inflammatory drugs.&#xD;
&#xD;
          -  Recent antibiotic treatment.&#xD;
&#xD;
          -  Psychiatric history.&#xD;
&#xD;
          -  Uncontrolled alcoholism or drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan J Vendrell, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nuria Taltavull, PhD</last_name>
    <phone>+34 977 297 998 626</phone>
    <phone_ext>29394</phone_ext>
    <email>taltavulln@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joan J Vendrell, PhD</last_name>
    <phone>+34619672912</phone>
    <email>jvortega2002@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Joan XXIII de Tarragona. IISPV</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Taltavull, PhD</last_name>
      <phone>+34659400526</phone>
      <email>voluntaris@iispv.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Investigacio Sanitaria Pere Virgili</investigator_affiliation>
    <investigator_full_name>Joan Josep Vendrell</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>diabetes</keyword>
  <keyword>intermittent fasting</keyword>
  <keyword>energy-sensing metabolites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data sharing will be upon request directly to the PI</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 28, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT05031572/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 28, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT05031572/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

